Debrisoquine oxidation phenotype during neuroleptic monotherapy.
The debrisoquine oxidation phenotype was determined in 91 schizophrenic patients on monotherapy with different neuroleptics and in 67 untreated healthy volunteers. The prevalence of poor metabolizers of debrisoquine was significantly higher in the patients (46.2%) than in the healthy subjects (7.5%). Treatment with phenothiazine antipsychotics (chlorpromazine, levomepromazine and thioridazine) was associated with a higher debrisoquine metabolic ratio than treatment with haloperidol. On the other hand, treatment with clothiapine appeared not to interfere with debrisoquine oxidation. Oral administration of 50 mg thioridazine daily to 8 healthy subjects resulted in a marked increase in the debrisoquine metabolic ratio and 4 of them were transformed into phenotypically poor metabolizers. The results confirm the fact that phenothiazines, and to a lesser extent haloperidol, inhibit the oxidative metabolism of debrisoquine. They show also that clothiapine administration does not disturb the debrisoquine metabolic ratio.
Spina
E
E
Institute of Pharmacology, School of Medicine, University of Messina, Italy.
Martines
C
C
Caputi
A P
AP
Cobaleda
J
J
Piñas
B
B
Carrillo
J A
JA
Benitez
J
J
D000328:Adult; D000368:Aged; D014150:Antipsychotic Agents / Q000494:pharmacology*; D003577:Cytochrome P-450 Enzyme System / Q000502:physiology; D003647:Debrisoquin / Q000378:metabolism*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010084:Oxidation-Reduction; D010641:Phenotype; D011110:Polymorphism, Genetic; D013881:Thioridazine / Q000494:pharmacology
D014150:Antipsychotic Agents; D003577:Cytochrome P-450 Enzyme System; D013881:Thioridazine; D003647:Debrisoquin